[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360289-105":59,"doc-detail-360289-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","18fpsma-1007-and-18ffdg-petct-in-metastatic-triple-negative-breast-cancer-a-prospective-head-to-head-comparison-and-assessment-of-psma-targeted-radioligand-therapy-applicability","[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in Metastatic Triple-negative Breast Cancer - A Prospective Head-to-Head Comparison and Assessment of PSMA-targeted Radioligand Therapy Applicability","","Triple-negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. PSMA imaging, widely used in prostate cancer, shows high expression in TNBC and may support both diagnosis and PSMA-targeted radioligand therapy (PSMA-RLT). This prospective study compares [18F]PSMA-1007 and [18F]FDG PET/CT for lesion detection and assesses whether PSMA uptake is sufficient to indicate PSMA-RLT applicability in metastatic TNBC patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/18fpsma-1007-and-18ffdg-petct-in-metastatic-triple-negative-breast-cancer-a-prospective-head-to-head-comparison-and-assessment-of-psma-targeted-radioligand-therapy-applicability/360289/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/18fpsma-1007-and-18ffdg-petct-in-metastatic-triple-negative-breast-cancer-a-prospective-head-to-head-comparison-and-assessment-of-psma-targeted-radioligand-therapy-applicability/360289.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of this prospective head-to-head study?","Question",{"text":112,"@type":113},"To compare [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in metastatic TNBC patients and assess whether PSMA uptake supports PSMA-targeted radioligand therapy applicability.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were imaging findings evaluated in patients?",{"text":117,"@type":113},"Qualitative and quantitative image analyses were performed to compare tracer uptake predominance and to evaluate the added value of diagnostic CT.",{"name":119,"@type":110,"acceptedAnswer":120},"Did any patients show [¹⁸F]PSMA-1007 uptake sufficient for PSMA-RLT using an SUV-based threshold?",{"text":121,"@type":113},"No. None of the patients demonstrated [¹⁸F]PSMA-1007 uptake levels sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360289,1790146619,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Lazutina etal. Cancer Imaging (2026) 26:71 Cancer Imaging  \n[https://doi.org/10.1186/s40644-026-01028-6](https://doi.org/10.1186/s40644-026-01028-6)  \nRESEARCH Open Access  \n[¹⁸ F]PSMA-1007 and [¹⁸ F]FDG PET/CTin patients with metastatic triple-negative breast cancer: a prospective head-to-head comparison and assessment of PSMAtargeted radioligand therapy applicability  \nTatiana Nikolaevna Lazutina 1, Aleksandr Igorevich Khalimon 1, Soslan Rolanovich Urtaev 1*, Malika Maratovna Khodzhibekova 1, Daria Yurevna Khodakova 1, Gulnara Faridovna Khamadeeva 1, Anastasia Igorevna Nikiforuk 1, Irina Valentinovna Pylova 1, Aleksei Victorovich Leontev 1 and Andrey Dmitrievich Kaprin 1  \nAbstract  \nBackground Triple-negative breast cancer (TNBC) is an aggressive molecular subtype of breast cancer with limited treatment approaches. Prostate-specific membrane antigen (PSMA), widely applied as a target for molecular imaging and radioligand therapy of prostate cancer, demonstrates the highest expression inTNBC across all molecular subtypes of breast cancer, and represents a promising target for imaging and treatment ofTNBC patients.  \nMethods This prospective study included 20 patients with metastatic TNBC who underwent both [¹⁸ F]PSMA- 1007 and [¹⁸ F]FDG PET/CT. Qualitative and quantitative image analysis was performed to determine the uptake predominance of one of the tracers and the added value of the diagnostic CT, as well as to assess the potential applicability of PSMA-targeted radioligand therapy (PSMA-RLT) .  \nResults A total of 229 lesions were identified using both [¹⁸ F]PSMA-1007 and [¹⁸ F]FDG PET/CT. Concordant and discordant lesions were observed for both tracers, with a greater number of discordant lesions identified by [¹⁸ F] PSMA-1007 . [¹⁸ F]FDG demonstrated higher uptake inTNBC lesions. An exception was observed in lung lesions, where no significant difference was found between tracers. The application of diagnostic CT revealed additional TNBC lesions that were not identified by PET, for each tracer. None of the patients demonstrated a [¹⁸ F]PSMA-1007 uptake level sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used.  \nConclusion Despite detectable [¹⁸ F]PSMA-1007 uptake inTNBC lesions, [¹⁸ F]FDG uptake was generally higher. Furthermore, the diagnostic CT can identify additional PET-negative lesions. Although PSMA expression is confirmed inTNBC, it may be insufficient to provide potential benefit from PSMA-RLT for this patient group.  \n*Correspondence:  \nSoslan Rolanovich Urtaev[urton1337@gmail.com](urton1337@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLazutina et al. Cancer Imaging (2026) 26:71 Page 2 of 10  \nKeywords PET/CT, [ 18 F]PSMA-1007,[ 18 F]Fluorodeoxyglucose, Triple-negative breast cancer, PSMA-targeted radioliga","cbCaiddBkMDYHhwu","https://ap.wps.com/l/cbCaiddBkMDYHhwu","pdf",1452813,"English","# Abstract\n# Background\n## Breast cancer and TNBC clinical need\n## PSMA and PSMA-RLT rationale\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What was the main purpose of this prospective head-to-head study?\",\"answer\":\"To compare [¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in metastatic TNBC patients and assess whether PSMA uptake supports PSMA-targeted radioligand therapy applicability.\"},{\"question\":\"How were imaging findings evaluated in patients?\",\"answer\":\"Qualitative and quantitative image analyses were performed to compare tracer uptake predominance and to evaluate the added value of diagnostic CT.\"},{\"question\":\"Did any patients show [¹⁸F]PSMA-1007 uptake sufficient for PSMA-RLT using an SUV-based threshold?\",\"answer\":\"No. None of the patients demonstrated [¹⁸F]PSMA-1007 uptake levels sufficient for potential PSMA-RLT application when a lesional SUV-based threshold was used.\"}]","[¹⁸F]PSMA-1007 and [¹⁸F]FDG PET/CT in Metastatic Triple-negative Breast Cancer - A Prospective Head-to-Head Comparison and Assessment of PSMA-targeted Radioligand Therapy Applicability | PDF",1790139498,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/601c71a28298be4ec6e510a0f6f70fa6.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad05fe8b1c063c13aa7b6307c38488be.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32a71f5025c7ab47a5b54484f1f10db3.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d13642bbc486056859667b3b749d98f9.webp",980,1306]